Contract Manufacturing, Biopharmaceutical Production

Scorpius BioManufacturing Announces New Microbial Capacity and New Interim President

March 22, 2023

In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.

The Logistics of Outsourcing Biologics

March 02, 2023

The trends shaping the growth of the biologics outsourcing industry demand attention.

Preparing for a New Wave of mRNA Technologies

February 16, 2023

To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.

CROs Gaining a Competitive Edge

February 15, 2023

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

Biopharmaceutical Manufacturing Growth

February 15, 2023

Growth in outsourcing has been the result of COVID-19 projects taking precedence, which has pushed some contract manufacturing to second-tier CDMOs.

Elektrofi Establishes Contract Manufacturing Agreement with Thermo Fisher Scientific

February 13, 2023

The technology is designed to enable patients to self-inject biologic-based therapies at home instead of a hospital setting.

Drug Solutions Podcast: Pharma Trends Dissected by 3 PR Agency Luminaries

January 10, 2023

Public relations agencies dissect pharmaceutical trends: Brandwidth Solutions, Orientation Marketing and White Matter Communications

Drug Solutions Podcast: Outsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 2

December 20, 2022

In this episode of the Drug Solutions Podcast, Meg Rivers discusses outsourcing strategies in biopharma with Jeff Henderson, key account manager of Vetter.

Drug Solutions Podcast: FDA Quality Management Maturity (QMM) Overseas Pilot Program Findings: Going Beyond the Regulations

December 07, 2022

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

November 17, 2022

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.